Who’s Taking the Stage at Digital RESI November?

12 Nov

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireNext week’s digital partnering event, Redefining Early Stage Investments (RESI), taking place November 17-19, is fast-approaching! RESI conferences provide early-stage players powerful partnering opportunities, but go beyond traditional pitching and partnering by offering insightful expert investor panels. These panels pull back the curtain to what investors look for when sourcing assets and developing partnerships. RESI’s panels highlight key perspectives relevant to the early-stage life science and healthcare ecosystem.

Panel themes range from Corporate Venture Capital to Early Stage Therapeutics Investments and will provide deep insights on investor perspectives, how investors and strategic partners view the current landscape, and how fundraising entrepreneurs can effectively approach the right investors, among other topics.

Registered attendees can block off their calendars directly in the partnering platform to make sure they don’t miss a panel that fits their interest. If you haven’t yet registered and are interested in hearing from key industry players, it is still not too late to register! Sign up to start partnering and learning from these key players. We hope you’ll join us!

EARLY STAGE THERAPEUTICS INVESTORS

  • Sascha Berger, Partner, TVM Capital Life Science
  • Z Haroon, Chairman and General Partner, Julz Co LLC
  • Sunil Shah, CEO, O2h Ventures
  • Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels
  • Travis Whitfill, Partner, Bios Partners

DIAGNOSTICS INVESTORS

  • Martin Pfister, Senior Investment Manager: Life Sciences, High-Tech Gründerfonds
  • Diana Saraceni, Founder, Managing Director, Panakes Partners
  • Noel Jee, Principal, Illumina Ventures
  • Jorge Aquino, Director, Ventures, Johns Hopkins Technology Ventures
  • Jorge Ramirez, Principal, H.I.G. BioHealth Partners

MEDICAL DEVICE INVESTORS

  • Flora Yao, Founding Partner, Ivy Elite Capital
  • George Li, Managing Partner, Proxima Ventures
  • Gary Gershony, Medical Device Committee, Life Science Angels
  • Rachel Rea, Director, Strategy & Portfolio Management, Surgical Innovations, Medtronic
  • Mishael Zohar, Associate, OrbiMed Advisors LLC

DIGITAL HEALTH

  • Ute Mercker, Investment Director, IBB Ventures
  • Terri Mead, Founder, Class Bravo Ventures
  • Sven Dethlefs, EVP Global Marketing & Portfolio, Teva Pharmaceuticals Industries
  • Sean Cheng, Senior Investment Manager, Philips Health Technology Ventures
  • Richard Proscia, Senior Associate, Providence Ventures

BIG PHARMA

  • Ravi Ramadas, Director, Immunology External Innovation, Global BD&L, Sanofi
  • Lisa Mendoza, Director, External Research & Alliances, Open Innovation – Digital Technologies, Bayer
  • Ronald Dorenbos, Founder and Managing Director, BioFrontline Ltd.
  • Tim Luker, Senior Director, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly & Co

CORPORATE VENTURE CAPITAL

  • Andy Merken, Partner, Corporate and Securities Co-Chair, Life Sciences, Burns & Levinson
  • David Hwang, Managing Director, Early Stage Partnerships, Agilent Technologies
  • Carrie Hurwitz Williams, Partner, McKesson Ventures
  • Victor Stone, Partner, Takeda Ventures
  • Hakan Goker, Vice President, Healthcare Team, M Ventures

New Sponsoring Opportunities at LSN’s Quarterly Healthtech Partnering Week

12 Nov

By Dennis Ford, Founder and CEO, Life Science Nation (LSN); Creator, Redefining Early Stage Investment (RESI) Conference Series, 4D Meets AI Conference, and Longevity, Health & Innovation Conference; Architect, Focus on Cures Accelerator; Owner, Boston Innovation Capital (BIC); Member, SPIC/FINRA Advisory Firm

New Sponsorship Program

Life Science Nation (LSN) has built a sourcing and funding global superstructure featuring elite global technology assets and the investors, Pharma and channel partners who seek them. The international infrastructure consists of early-stage life science buyers and sellers, each with updated curated data profiles that are matched up at LSN’s dedicated partnering events. In 2021, these partnering events will join forces to become a global quarterly Healthtech Partnering Week, featuring RESI, 4D Meets AI, as well as Longevity, Health & Innovation partnering conferences. These events will take place in conjunction with global life science hubs, enabling fundraising CEOs to leverage the partnering system as part of a global capital raising campaign. Sponsorship at these events help companies gain unprecedented visibility into the early-stage life science community, and also leverage LSN’s close-knit network of key decision-makers to make promising connections with future clients and strategic partners. The sponsorship program is designed to help organizations increase global exposure through high visibility branding and messaging, target and source assets and strategic partnerships, advertise products and services through programming and direct contact with industry leaders. To learn more about sponsorship opportunities, download our sponsorship brochure.

The Digital Experience: 2020-2021

The Covid-19 pandemic has challenged the global economy and business climate, but LSN has not slowed down. On the contrary, LSN has accelerated since March 2020 through its focus on deal-making. LSN partnering conferences are experiential, interactive, and focus on building relationships and successful transactions. LSN stands out among other educational life science networks for this mission. LSN’s continued mission has been to connect buyers and sellers to move the needle in the early-stage life science partnering arena. Partnering is neither a trend nor conference sideshow, rather an essential matching exercise that needs curated profiles of both the buyer and the seller, and an integrated search feature that can match companies based on mutual fit.

Matching Buyers and Sellers Together

LSN matches buyers and sellers based on stage of development and product fit through curating detailed up-to-date profiles of every constituent of the two groups. This method enables efficient partnering at LSN events and avoids empty tables and ill-fitting meetings. Matching requires profile curation and detailed database management, therefore, a large volume of LSN resources go towards maintaining and constantly improving this imperative feature. In addition to efficient matching, LSN offers educational resources available to fundraising executives including LSN CEO, Dennis Ford’s book, The Life Science Executive Fundraising Manifesto which guides scientist-entrepreneurs through the concepts of building branding and messaging. Additional resources include free tutorials and webinars aimed at preparing CEOs to book meetings with investors effectively, which includes adroit messaging and a 4-step follow-up process, which has been proven to advance the needle from 4-6 meetings to 12-20 meetings. Fundraising is a numbers game and understanding how to get the most of out of these global partnering events is the key to a successful capital raise.

Partnering is an Ongoing Experiential Activity

The LSN partnering theme is that it is a crucial, ongoing, and experiential activity. LSN believes that partnering cannot be done once or twice a year, as business deals do not work that way. In the life science arena, it can take 9-18 months to put a deal together. This means that all buyers and sellers need a simple, low-cost, straight-forward vehicle to meet and engage monthly in order to find new opportunities for their respective pipelines, advance a conversation, continue to vet and develop a relationship, or close deals. LSN’s recent entrée of digital events has proved and invigorated this concept. Life science is a virtual third-party service domain, making a new, hybrid, global ecosystem timely and compelling. We look forward to advancing life-saving deals through our Healthtech Partnering Weeks, and hope you’ll consider partnering with us. To learn more about sponsorship opportunities, download our sponsorship brochure.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!

International
Greg Mannix
Chief Conference Officer, Vice President International BD
g.mannix@lifesciencenation.com

West Coast (USA)
Candice He
Global Investment Strategist
c.he@lifesciencenation.com
​
East Coast (USA)
Ashley Zborowski
Director of Business Development
a.zborowski@lifesciencenation.com

Hot Investor Mandate: Western Europe-Based VC Firm Invests Up to €20M in Innovative Therapeutics Addressing Unmet Need, Open to Various Modalities

12 Nov

A leading European independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. The firm has raised three funds to date. The investments typically range from €5 million to €20 million, including additional capital for follow-on investments.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Life Science Investment Arm of Global PE Firm Invests Up to $20M in Clinical Stage Therapeutics, Medical Devices, Diagnostics

12 Nov

A life science investment arm of a global private equity has offices across the USA. The fund may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide.

The firm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the firm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the firm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The firm will consider investments in any indication or technology area.

The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, the firm is open to working to fill or change the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Venture Capital Firm Invests in Medical Devices & Diagnostics Companies in Oncology, Cardiovascular Disease, and More

12 Nov

A venture capital firm based in the USA is specializing in early stage opportunities in med-tech, diagnostics, and instruments. Currently, the firm has a total AUM of $125 million. Typically, the firm initially invests in a start-up at the early stage, but reserves capital for participation later on. The firm typically makes a first investment in the range of $1-3 million, but is open to making larger or smaller allocations as opportunities arise. The firm expects to invest a total in the range of $7-12 million in a given portfolio company as it makes progress toward a successful exit. The firm prefers to act as a lead investor for early stage deals.

The firm is most interested in companies developing medical devices, diagnostics tools and instrumentation. The firm is looking for companies targeting global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. The firm is willing to invest in companies that are pre-prototype as well as those that have a working prototype of their product.

The firm looks to act as a long term strategic partner with its portfolio companies. The firm looks for experienced management teams and generally looks to take a board seat into companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based Large Pharma Interested in Global R&D Partnership and Investment Opportunities in Novel Therapeutics & Medical Devices

12 Nov

A listed pharmaceutical company in Asia with 5 Billion of assets under management is actively seeking global R&D partnerships and investment opportunities. Through over 2 decades of arduous efforts, it has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area.

The firm has focused interest in Traditional Chinese Medicine granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm’s Healthcare Fund Primarily Invests in Therapeutics, with Strong Interests in Immunology & Oncology and Novel Platforms

11 Nov

A corporate venture arm invests across multiple funds, with each fund focused on a sector of strategic interest to the parent organization. The firm typically leads or co-leads rounds as a member of a syndicate of investors. The firm is actively seeking new investment opportunities across all funds.

The firm’s healthcare fund is looking for early stage companies working primarily within therapeutics. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat, and is able to invest globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →